DE69310065D1 - Verwendung von 2-(3,4-Dimethoxycinnamoyl)aminobenzoesäure zur Herstellung eines Arzeimittels zur Behandlung der Restenose - Google Patents

Verwendung von 2-(3,4-Dimethoxycinnamoyl)aminobenzoesäure zur Herstellung eines Arzeimittels zur Behandlung der Restenose

Info

Publication number
DE69310065D1
DE69310065D1 DE69310065T DE69310065T DE69310065D1 DE 69310065 D1 DE69310065 D1 DE 69310065D1 DE 69310065 T DE69310065 T DE 69310065T DE 69310065 T DE69310065 T DE 69310065T DE 69310065 D1 DE69310065 D1 DE 69310065D1
Authority
DE
Germany
Prior art keywords
dimethoxycinnamoyl
restenosis
medicament
manufacture
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69310065T
Other languages
English (en)
Other versions
DE69310065T2 (de
Inventor
Hideo Tamai
Kinzo Ueda
Yung-Sheng Hsu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Publication of DE69310065D1 publication Critical patent/DE69310065D1/de
Application granted granted Critical
Publication of DE69310065T2 publication Critical patent/DE69310065T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
DE69310065T 1992-09-14 1993-08-26 Verwendung von 2-(3,4-Dimethoxycinnamoyl)aminobenzoesäure zur Herstellung eines Arzeimittels zur Behandlung der Restenose Expired - Fee Related DE69310065T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP4288086A JP2617407B2 (ja) 1992-09-14 1992-09-14 血管内膜細胞過剰増殖疾患の予防および治療剤

Publications (2)

Publication Number Publication Date
DE69310065D1 true DE69310065D1 (de) 1997-05-28
DE69310065T2 DE69310065T2 (de) 1997-11-20

Family

ID=17725612

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69310065T Expired - Fee Related DE69310065T2 (de) 1992-09-14 1993-08-26 Verwendung von 2-(3,4-Dimethoxycinnamoyl)aminobenzoesäure zur Herstellung eines Arzeimittels zur Behandlung der Restenose

Country Status (7)

Country Link
US (1) US5385935A (de)
EP (1) EP0588518B1 (de)
JP (1) JP2617407B2 (de)
KR (1) KR100252410B1 (de)
CA (1) CA2106172C (de)
DE (1) DE69310065T2 (de)
HK (1) HK1005425A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6251920B1 (en) 1993-05-13 2001-06-26 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US6306421B1 (en) 1992-09-25 2001-10-23 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6395494B1 (en) 1993-05-13 2002-05-28 Neorx Corporation Method to determine TGF-β
US5770609A (en) 1993-01-28 1998-06-23 Neorx Corporation Prevention and treatment of cardiovascular pathologies
US5981568A (en) 1993-01-28 1999-11-09 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US6491938B2 (en) 1993-05-13 2002-12-10 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5595722A (en) * 1993-01-28 1997-01-21 Neorx Corporation Method for identifying an agent which increases TGF-beta levels
US6663881B2 (en) 1993-01-28 2003-12-16 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
JPH08510451A (ja) * 1993-05-13 1996-11-05 ネオルックス コーポレイション 異常増殖性平滑筋細胞に関連した病因の予防及び治療
US5824644A (en) * 1994-07-07 1998-10-20 G. D. Searle & Co. Method of attenuating arterial stenosis
US20030083733A1 (en) * 1997-10-10 2003-05-01 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5837313A (en) * 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US6099562A (en) * 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US20020091433A1 (en) * 1995-04-19 2002-07-11 Ni Ding Drug release coated stent
US7611533B2 (en) * 1995-06-07 2009-11-03 Cook Incorporated Coated implantable medical device
AU6277396A (en) * 1995-06-07 1996-12-30 Neorx Corporation Prevention and treatment of cardiovascular pathologies with tamoxifen analogues
CZ258598A3 (cs) * 1996-02-15 1998-11-11 Kissei Pharmaceutical Co., Ltd. Inhibitor neovaskularizace
JPH09278653A (ja) * 1996-04-05 1997-10-28 Santen Pharmaceut Co Ltd 網膜疾患治療剤
US6019104A (en) * 1996-12-30 2000-02-01 Kissei Pharmaceutical Co., Ltd. Method for the treatment or prevention of restenosis associated with coronary intervention
US6114383A (en) * 1997-02-14 2000-09-05 Kissei Pharmaceutical Co., Ltd. Drugs inhibiting progress of pterygium and postoperative recurrence of the same
US6511477B2 (en) * 1997-03-13 2003-01-28 Biocardia, Inc. Method of drug delivery to interstitial regions of the myocardium
RU2207852C2 (ru) * 1997-04-18 2003-07-10 Киссеи Фармасьютикал Ко., Лтд. Средства для предотвращения или лечения болезней, связанных с чрезмерной пролиферацией эпителиальных пигментных клеток сетчатки
DE69935716T2 (de) * 1998-05-05 2007-08-16 Boston Scientific Ltd., St. Michael Stent mit glatten enden
CN1345237A (zh) * 1999-02-03 2002-04-17 史密丝克莱恩比彻姆公司 预防或降低与冠脉介入有关的心血管事件的方法
CA2361578A1 (en) * 1999-02-03 2000-08-10 David C. U'prichard Method for the prevention or reduction of cardiovascular events associated with coronary intervention
WO2001005394A1 (fr) * 1999-07-16 2001-01-25 Kissei Pharmaceutical Co., Ltd. Agents inhibant les reactions de rejet chronique faisant suite a une greffe d'organe
US20060216313A1 (en) * 1999-08-10 2006-09-28 Allergan, Inc. Methods for treating a stricture with a botulinum toxin
US6767544B2 (en) * 2002-04-01 2004-07-27 Allergan, Inc. Methods for treating cardiovascular diseases with botulinum toxin
WO2001062241A1 (en) * 2000-02-23 2001-08-30 Smithkline Beecham Corporation Method for the prevention or reduction of vascular access dysfunction
US6613083B2 (en) * 2001-05-02 2003-09-02 Eckhard Alt Stent device and method
WO2004002367A1 (fr) * 2002-06-27 2004-01-08 Microport Medical (Shanghai) Co., Ltd. Stent eluant des medicaments
US20080306126A1 (en) * 2004-01-05 2008-12-11 Fonseca Vivian A Peroxisome proliferator activated receptor treatment of hyperhomocysteinemia and its complications
US7473738B2 (en) * 2004-09-30 2009-01-06 Johnson & Johnson Vision Care, Inc. Lactam polymer derivatives
US8668703B2 (en) * 2006-12-01 2014-03-11 Wake Forest University Health Sciences Medical devices incorporating collagen inhibitors
EP2455077B1 (de) 2009-06-17 2014-06-11 National University Corporation Kumamoto University Prophylaxe- und/oder behandlungsmittel für dysmenorrhoe

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4070484A (en) * 1973-01-18 1978-01-24 Kissei Pharmaceutical Co., Ltd. Antiallergic composition containing aromatic carboxylic amide derivatives and method of using the same
JPS5640710B2 (de) * 1973-01-18 1981-09-22
US4337270A (en) * 1980-05-21 1982-06-29 Hisamitsu Pharmaceutical Co., Inc. Novel anthranilic acid derivatives

Also Published As

Publication number Publication date
EP0588518A1 (de) 1994-03-23
KR100252410B1 (ko) 2000-05-01
HK1005425A1 (en) 1999-01-08
JPH06135829A (ja) 1994-05-17
CA2106172A1 (en) 1994-03-15
EP0588518B1 (de) 1997-04-23
KR940006578A (ko) 1994-04-25
US5385935A (en) 1995-01-31
CA2106172C (en) 2001-01-02
JP2617407B2 (ja) 1997-06-04
DE69310065T2 (de) 1997-11-20

Similar Documents

Publication Publication Date Title
DE69310065D1 (de) Verwendung von 2-(3,4-Dimethoxycinnamoyl)aminobenzoesäure zur Herstellung eines Arzeimittels zur Behandlung der Restenose
ATE206919T1 (de) Verwendung des wirkstoffs flupirtin zur herstellung eines arzneimittels zur bekämpfung von muskelverspannungen
DE122005000002I1 (de) Verwendung von Venlafaxin oder eines Aryloxy-Propanaminderivates zur Herstellung eines Medikaments zur Behandlung von Inkontinenz.
DE69705877D1 (de) Verwendung von Anionenaustauscherharzen zur Herstellung eines Arzneimittels zur Behandlung der Hyperphosphatemie
DE69001484D1 (de) Verwendung von menschlichen bcdf fuer die herstellung einer zusammensetzung fuer die behandlung von thrombocytopenia.
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
DE68924714D1 (de) Verwendung von essentiellen fettsäuren zur herstellung eines medikaments zur behandlung von ekzemen.
ATE335487T1 (de) Verwendung von pyridazino 4,5-(b)ö-indole-1- acetamide derivaten zur herstellung eines arzneimittels zur behandlung von durch periphere benzodiazepinrezeptoren-störungen verursachte krankheiten
DE69637449D1 (de) Verwendung von alpha-hydroxysäuren zur herstellung eines arzneimittels für die behandlung von entzündungen
DE69910202D1 (de) EGR-1 zur Herstellung eines Medikamentes zur Behandlung von Wunden
DE69635298D1 (de) Verwendung von Acetylsalicylsäuren zur Herstellung eines Medikaments für die Behandlung von Hautverletzungen
DE69423577D1 (de) Verwendung von Oenothein B zur Herstellung eines Medikaments zur Behandlung der durch Hyperandrogenität bedingte Störungen.
DE69232911D1 (de) Verwendung eines polyhydroxybenzamids oder dessen Derivat zur Herstellung eines Medikaments für die Behandlung von viralen Infektionen
DE50010234D1 (de) Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
DE69007065D1 (de) Verwendung von Diadenosin-5',5'''-p1,p4-tetraphosphat zur Herstellung eines Arzneimittels zur Behandlung von Herzkrankheiten.
DE69005978D1 (de) Verwendung von Actinonin zur Herstellung eines Medikamentes zur Inhibierung der Angiogenese.
ATE183088T1 (de) Arzneimittel zur behandlung von hauterkrankungen
DE68905657D1 (de) Verwendung von arginin-aspartat zur herstellung eines arzneimittels zur behandlung gewisser gedaechtnisstoerungen.
AU8505991A (en) Use of compositions containing 2-(6'-substituted-2'-naphthyl)-acetic acid derivatives for the treatment of respiratory disorders
DE69620786D1 (de) Verwendung von cholinesterase-inhibitoren für die herstellung eines medikaments zur behandlung von xerostomie
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
HUP9904029A3 (en) Use of 2-(3,4-dimethoxycinnamoyl)aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis
DE3483944D1 (de) Verwendung von selektiv peripheren dopamin-antagonisten zur herstellung eines arzneimittels zur topischen behandlung von okularer hypertension.
DE69610045D1 (de) Verwendung eines Rohpflanzenextraktes zur Herstellung eines Arzneimittels zur Behandlung von HIV-Infektionen
DE69124415D1 (de) Verwendung von 15-Dehydroxy-16-Oxoprostaglandin bei der Behandlung von allergischen Erkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee